Q-omics provides the consensus-scored OBP2B profile across patient tissues and cancer cell-line models. OBP2B expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, OBP2B is differentially expressed in 8, with the highest sampling consensus in KIRC. Additionally, OBP2B RNA expression shows 6,894 significant pathway-activity associations, with the highest sampling consensus in KIRC. Together, these results highlight UCS, and KIRC as cancer lineages where OBP2B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for OBP2B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes OBP2B survival associations across molecular data types. OBP2B RNA expression shows survival associations in the most cancer types (20), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible OBP2B RNA expression–survival associations across cancer types. High OBP2B expression shows unfavorable associations in UCS, KICH, KIRC and DLBC, but favorable associations in LAML and UCEC. The UCS Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCS as the clearest survival context for OBP2B RNA expression.
This table summarizes OBP2B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for OBP2B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. OBP2B shows lower tumor expression in BRCA and higher tumor expression in KIRC, COAD, THCA, CHOL and STAD. The KIRC box plot shows higher OBP2B RNA expression in tumor versus normal tissue (log2 FC = +0.119, t-test p < 0.001).
This table shows molecular features associated with OBP2B in patient tissues and cancer cell lines. In patient samples, OBP2B shows the broadest associations at the RNA and protein expression levels, with KIRC recurring as the lineage with the largest associated feature set. In cancer cell lines, OBP2B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in SKIN and PANCREAS.
